GSK

3 days ago · seekingalpha.com

Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventory reductions and broader RSV demand issues.

3 days ago · zacks.com

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

4 days ago · seekingalpha.com

GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director Tony Wood - Chief Scientific Officer and Head of R&D Nina Mojas - President of Global Product Strategy Julie Brown - CFO & Executive Director David Redfern - President of Corporate Development Conference Call Participants James Gordon - Barclays Bank PLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Michael Leuchten - Jefferies LLC, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Matthew Weston - UBS Investment Bank, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Presentation Jeff McLaughlin VP of Investor Relations & Interim Head of Investor Relations Welcome, everyone, and thanks for joining GSK's Q3 2026 results.

4 days ago · marketbeat.com

GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%.

5 days ago · zacks.com

GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.

5 days ago · benzinga.com

GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.

5 days ago · seekingalpha.com

GSK plc delivered strong results today. In the third quarter, revenue and non-GAAP EPS grew 5.7% and 8.2% quarter-on-quarter, respectively. Cabenuva, GSK's long-acting HIV treatment, generated $641 million in sales, up 35.2% year over year.

5 days ago · zacks.com

GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.

5 days ago · wsj.com

The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.

5 days ago · reuters.com

GSK beat third-quarter sales and profit expectations ​on Wednesday, helped ‌by demand for specialty medicines, suggesting CEO Luke Miels' efforts ​to accelerate growth ​and prepare the drugmaker ⁠for